IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Iksuda Therapeutics Ltd.
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Hoag Memorial Hospital Presbyterian · Newport Beach, CA
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Tennessee · 1
- Tennessee Oncology · Nashville, TN
Texas · 1
- START Dallas - Fort Worth · Fort Worth, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.